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RESEARCH ARTICLE Open Access
Tumor-released autophagosomes induces
CD4+ T cell-mediated immunosuppression
via a TLR2–IL-6 cascade
Yong-Qiang Chen1†, Peng-Cheng Li1†, Ning Pan1†, Rong Gao1, Zhi-Fa Wen1, Tian-Yu Zhang1, Fang Huang1,
Fang-Yuan Wu2, Xi-Long Ou3, Jin-Ping Zhang5, Xue-Jun Zhu1,7, Hong-Ming Hu1,4, Kang Chen6,7,
Yun-Lang Cai2* and Li-Xin Wang1*
Abstract
Background: CD4+ T cells are critical effectors of anti-tumor immunity, but how tumor cells influence CD4+ T cell
effector function is not fully understood. Tumor cell-released autophagosomes (TRAPs) are being recognized as
critical modulators of host anti-tumor immunity during tumor progression. Here, we explored the mechanistic
aspects of TRAPs in the modulation of CD4+ T cells in the tumor microenvironment.
Methods: TRAPs isolated from tumor cell lines and pleural effusions or ascites of cancer patients were incubated
with CD4+ T cells to examine the function and mechanism of TRAPs in CD4+ T cell differentiation and function.
TRAPs-elicited CD4+ T cells were tested for their suppression of effector T cell function, induction of regulatory B
cells, and promotion of tumorigenesis and metastasis in a mouse model.
Results: Heat shock protein 90α (HSP90α) on the surface of TRAPs from malignant effusions of cancer patients and
tumor cell lines stimulated CD4+ T cell production of IL-6 via a TLR2–MyD88–NF-κB signal cascade. TRAPs-induced
autocrine IL-6 further promoted CD4+ T cells secretion of IL-10 and IL-21 via STAT3. Notably, TRAPs-elicited CD4+ T
cells inhibited CD4+ and CD8+ effector T cell function in an IL-6- and IL-10-dependent manner and induced IL-10-
producing regulatory B cells (Bregs) via IL-6, IL-10 and IL-21, thereby promoting tumor growth and metastasis.
Consistently, inhibition of tumor autophagosome formation or IL-6 secretion by CD4+ T cells markedly retarded
tumor growth. Furthermore, B cell or CD4+ T cell depletion impeded tumor growth by increasing effector T cell
function.
Conclusions: HSP90α on the surface of TRAPs programs the immunosuppressive functions of CD4+ T cells to
promote tumor growth and metastasis. TRAPs or their membrane-bound HSP90α represent important therapeutic
targets to reverse cancer-associated immunosuppression and improve immunotherapy.
Keywords: Extracellular vesicles (EVs), Tumor-released autophagosome (TRAP), CD4+ T cell, Regulatory B cell, IL-6,
Heat shock protein 90α (HSP90α)
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Background
CD4+ T cells play a critical role in modulating both in-
nate and adaptive anti-tumor immune responses. Re-
search over the past two decades has revealed that CD4+
effector T cells, especially IFN-γ-producing T helper 1
(Th1) cells, can exhibit anti-tumor activity [1]. However,
other subtypes of tumor-infiltrating CD4+ T cells may
play a pro-tumorigenic role in the tumor microenviron-
ments via the secretion of inflammatory or regulatory
cytokines, such as interleukin (IL)-6, IL-10, IL-17, IL-21,
and transforming growth factor (TGF)-β, as the abun-
dance of such CD4+ T cells has been associated with a
poor clinical outcome of various types of cancer [1–4].
It has also become clear that many tumor-derived mole-
cules or extracellular vesicles likely influence the differ-
entiation of CD4+ T cells [5, 6]. However, the precise
mechanisms underlying CD4+ T cell differentiation and
functions in the tumor microenvironment are not com-
pletely understood.
Extracellular vesicles (EVs) have emerged as a new mode
of intercellular communication by functioning as the car-
riers of bioactive molecules to influence the extracellular
environment and the immune system [6–8]. Recent evi-
dences indicate that secretory autophagy, in contrast to
canonical autophagy, is an alternative non-degradative
mechanism for cellular trafficking and unconventional se-
cretion of proteins and small molecules [9], such as IL-1β
[10], high mobility group box 1 (HMGB1) [11], adenosine
triphosphate (ATP) [12], TGF-β [13], and lysozyme [14].
More importantly, secretory autophagosomes carrying
cytoplasmic cargoes, including tumor-specific antigens or
viruses, fail to fuse with lysosomes and instead are re-
leased into the extracellular environment by the cells
under stress [15, 16].
We have previously found extracellular secretory autop-
hagosomes from the supernatant of tumor cells or malig-
nant effusions and ascites of cancer patients [17, 18], and
have termed such tumor-released autophagosomes
TRAPs. We confirmed that TRAPs can be taken up by
phagocytes such as neutrophils and macrophages, as well
as B cells, and endow them with immunosuppressive ac-
tivities [18–20]. These observations highlight that TRAPs
are part of an elaborate network of tumor-derived vesicles
that can reroute the immune response towards a cancer-
promoting direction and should be targeted to improve
cancer therapy. However, the mechanistic aspects of
TRAPs in the modulation of immune cell function, espe-
cially the key anti-tumor effector cell, CD4+ T cell, in the
tumor microenvironment and during tumor progression
are unclear.
Here, we demonstrate that TRAPs could educate
CD4+ T cells to produce IL-6 that functions in an auto-
crine manner to promote the production of IL-10 and
IL-21. TRAPs-elicited CD4+ T cells (TTRAP) directly
inhibit the anti-tumor IFN-γ response of CD4+ T and
CD8+ T cells and also induce IL-10+ Bregs, which cre-
ates a favorable environment to facilitate tumor growth
and metastasis. Mechanistic studies revealed that
membrane-bound HSP90α on intact TRAPs is crucial
for inducing IL-6 production in CD4+ T cells via a
TLR2–MyD88–NF-κB signal cascade. Moreover, auto-
crine IL-6 further stimulates CD4+ T cells to produce
IL-10 and IL-21 via STAT3. Our study unveils novel cel-
lular and molecular mechanisms of tumor-derived extra-
cellular vesicles in regulating CD4+ effector T cell
function and pinpoint TRAPs as a therapeutic target for
cancer immunotherapy.
Materials and methods
Human subjects
Malignant pleural effusions and ascites were collected
from cancer patients pathologically diagnosed with mul-
tiple cancer types. The clinicopathological characteristics
of the enrolled patients are presented in Additional file 1:
Table S1. The study was approved by the Ethics Com-
mittee for Human Studies of Southeast University
(protocol 2016ZDKYSB112).
Mice
C57BL/6 female mice were purchased from the Com-
parative Medicine Center of Yangzhou University.
Tlr4−/−, Tlr2−/−, Myd88−/− and OT-I mice were pur-
chased from the Nanjing Biomedical Research Institute
of Nanjing University (Nanjing, China). Il6−/− mice were
gifts from Dr. Jinping Zhang (Institutes of Biology and
Medical Sciences, Soochow University, Suzhou, China).
Mice were maintained in the barrier facility at Southeast
University. All animal experiments were approved by the
Institutional Animal Care and Use Committee of South-
east University.
Cell culture
The murine hepatic carcinoma line Hepa1–6, melanoma
line B16F10, Lewis lung carcinoma line LLC, lymphoma
line EL4, and the human melanoma line A375, hepatic car-
cinoma line HepG2 and breast carcinoma line MDA-MB-
231 were cultured in complete RPMI-1640 medium with
10% FBS (Gibco), 100 U/ml penicillin and 0.1mg/ml
streptomycin at 37 °C in a 5% CO2 incubator. Becn1
knockdown (Becn1 KD) and negative control B16F10
cells (Becn1 NC) were established by using lentivirus
expressing Becn1-targeting (5′- GCGGGAGUAUA
GUGAGUUUTT-3′) and scrambled (5′-TTCTCCGAA
CGTGTCACGTAA-3′) shRNA (Hanbio Biotechnol-
ogy, Shanghai, China), respectively.
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Chemicals
The inhibitors PD98059, SP600125, SB203580, LY294002,
BAY11–7082, and Stattic were purchased from MCE
(Shanghai, China). Recombinant murine IL-2 and IL-12
were purchased from PeproTech (Rocky Hill, USA). CFSE
were purchased from Invitrogen/Thermo Fisher Scientific.
IL-6, IL-10 and IL-21 neutralizing antibodies were pur-
chased from R&D Systems. Lymphocyte separation media
were purchased from MultiSciences (Hangzhou, China).
All other reagents were obtained from Sigma-Aldrich (St.
Louis, MO).
TRAPs purification and characterization
Tumor cells were seeded in a T175 flask in complete
RPMI-1640 culture medium supplemented with 10%
heat-inactivated FBS (Gibco), 100 U/ml penicillin, and
0.1 mg/ml streptomycin and incubated for 3–4 days at
37 °C, 5% CO2 until 100% confluency was reached.
Tumor cell culture supernatants were collected for
TRAPs isolation as described previously [18, 20]. Briefly,
supernatants were centrifuged at 2000 rpm for 10min to
remove whole cells and debris. The supernatants were
further centrifuged at 12,000 g for 30 min to harvest the
TRAPs-containing pellet. The TRAPs-containing pellet
was washed three times with PBS and isolated with mag-
netic beads (Miltenyi Biotec) combined with LC3b anti-
body (Cell Signaling Technology) for TRAPs. The purity
of TRAPs was analyzed by flow cytometry and western
blot. The size of TRAPs was determined by dynamic
light scattering using a Malvern Instrument.
Primary cell isolation
Mouse splenic B cells (Invitrogen, 11422D), CD4+ T cells
(Invitrogen, 11415D), CD8+ T cells (Invitrogen, 11417D)
and human peripheral blood CD4+ T cells (Miltenyi Bio-
tec, 130–045-101) were purified by magnetic-activated
cell sorting (MACS) following the manufacturer’s in-
structions. After the MACS, the purity of T and B cells
were > 95% as assessed by flow cytometry.
Flow cytometry
Purified CD4+ T or CD8+ T cells were cultured in a 24-
well plate pre-coated with 2 μg/ml anti-CD3 (BD Biosci-
ences, 550,275) and 2 μg/ml anti-CD28 mAb (BD Biosci-
ences, 553,294) in the presence of 50 U/ml IL-2
(PeproTech), purified TRAPs and 30% culture superna-
tants from CD4+ T cells or B cells. In some cases, cul-
ture supernatants from CD4+ T cells or B cells were
pretreated with neutralizing mAbs against IL-6, IL-10, or
IL-21 for 1 h at 4 °C and subsequently exposed to T cells
or B cells. Three days later, IFN-γ+ CD4+ T, IFN-γ+
CD8+ T or IL-10+ B cells were evaluated by flow cytom-
etry. For intracellular staining, the cells were stimulated
with the ovalbumin (OVA) protein or anti-CD3 and
anti-CD28 mAbs at 37 °C for 24 or 72 h. Leukocyte acti-
vation cocktail and GolgiPlug (BD Biosciences) were
added to the culture 5 h prior to flow cytometric ana-
lysis. Subsequently, the cells were stained with anti-
bodies specific to the various surface molecules, fixed
and permeabilized with a Fixation/Permeabilization
Kit (BD Biosciences), and finally stained with anti-
bodies against the various intracellular molecules. To
detect Bcl-6 and Foxp3, the cells were fixed and
permeabilized using a Transcription Factor Buffer Set
(BD Biosciences). Data were acquired using a FACS
Calibur analyzer (BD Biosciences) and analyzed by
FlowJo. The gates were set according to the staining
by isotype-matched control antibodies of the respect-
ive cells. The fluorochrome-conjugated Abs used are
listed in Additional file 1: Table S2.
Quantitative real-time PCR
Total RNA from CD4+ T cells was isolated with TRIzol
reagent (Invitrogen) and reverse-transcribed using 5 ×
PrimeScriptRT Master Mix (Takara), following the man-
ufacturer’s instructions. The specific primers used to
amplify the genes are listed in Additional file 1: Table
S3. The PCR was performed in triplicate using Fast Start
Universal SYBR Green Master (ROX) (Roche Life Sci-
ence) in a StepOne Real-Time PCR System (Thermo
Fisher Scientific). GAPDH was used as an internal
standard.
Elisa
Cytokines in the sera or cell culture supernatants were
quantified using ELISA kits according to the manufac-
turer’s protocol. ELISA sets were purchased from
eBioscience (IL-6 and IL-10) and R&D Systems (IL-21).
Western blot
The proteins samples were extracted from CD4+ T cells
with RIPA lysis buffer. They were separated and trans-
ferred as previously described [21]. The membranes
were blocked with 5% BSA in TBST for 1 h and separ-
ately incubated with the primary antibodies overnight at
4 °C. After washing with TBST buffer, the membranes
were incubated with horseradish peroxidase-conjugated
secondary antibodies for 1 h. The results were visualized
by enhanced chemiluminescence according to the manu-
facturer’s protocol. The primary antibodies used are
listed in Additional file 1: Table S4.
Animal models
Wild type C57BL/6 mice or Il6−/− C57BL/6 mice were
subcutaneously inoculated with B16F10, B16F10 Becn1
NC or B16F10 Becn1 KD cells (2 × 105 cells/mouse).
Tumor growth was measured using a caliper. On day 21,
draining lymph nodes (dLN), spleens or tumor tissues
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were harvested from tumor-free or tumor-bearing mice.
The frequencies of IL-10+ CD4+ T cells, IL-21+ CD4+
T cells, or IL-10+ B cells were evaluated by flow cy-
tometry after ex vivo stimulation with the leukocyte
activation cocktail and GolgiPlug (BD Biosciences) for
5 h. In the subcutaneous tumor model, B16F10 tumor
cells (2 × 105 cells/mouse) and CD4+ T cells treated
with TRAPs, or B cells treated with the indicated cul-
ture conditions (2 × 106 cells/mouse) were subcutane-
ously injected into the right flank of C57BL/6 mice.
Subcutaneous tumor growth was monitored and mea-
sured using vernier calipers. In the tumor metastasis
model, B16F10 tumor cells (5 × 105 cells/mouse) were
intravenously injected into C57BL/6 mice and
TRAPs-treated or untreated CD4+ T cells or B cells
(5 × 106 cells/mouse) treated with the indicated cul-
ture conditions were injected every other day for 3
times. Three weeks later, mice were sacrificed, and
the tumor nodules in the lungs were examined. To
evaluate the role of CD4+ T cells and B cells treated
with the indicated culture conditions in OVA-loaded
DC−mediated specific immune response, C57BL/6
mice were adoptively transferred with OT-I spleno-
cytes (1 × 107 cells/mouse) on day 0 and vaccinated
with OVA-loaded DCs (1 × 106 cells/mouse) on days
1, 4, and 7. After intravenous administration of CD4+
T cells and B cells on days 2, 5, and 8, mice from
each group were sacrificed on day 14 and the fre-
quency and number of CD8+Vβ5.1+ T cells were eval-
uated by flow cytometry. The frequency of IFN-γ+
CD4+ and CD8+ T cells in the spleens was deter-
mined by intracellular cytokine staining after ex vivo
stimulation with the OVA protein for 24 h.
T and B cell depletion
C57Bl/6 mice (n = 5/group) were inoculated subcutane-
ously in the flank with 1 × 106 Becn1-NC or Becn1-KD
B16F10 cells. On day 9, the tumor-bearing mice were
subsequently depleted of either CD4+ T cells, CD8+ T
cells or CD20+ B cells by intravenous administration of
250 μg/mouse of anti-mouse CD4 (clone GK1.5, BioX-
Cell) or anti-mouse CD8 (clone 2.43, BioXCell) twice
weekly throughout the course of tumor growth, or
250 μg of anti-mouse CD20 (clone SA271G2, BioLe-
gend), respectively. Control mice were treated similarly
but with isotype-matched control antibodies. Depletion
was confirmed by staining of peripheral blood cells with
anti-mouse CD4 (RM4–5, BD Pharmingen), anti-mouse
CD8 (clone 53–6.7, BioLegend), or anti-mouse CD19
(clone 6D5, BioLegend).
Statistical analysis
Data were derived from at least 3 independent experi-
ments and analyzed using GraphPad Prism 5.0 software.
Multiple group comparisons were performed by one-
way ANOVA and the Tukey-Kramer multiple test. Com-
parisons between 2 groups were performed using un-
paired Student’s t-test or Mann-Whitney U test. P < 0.05
was considered significant.
Results
TRAPs induce CD4+ T cells to produce IL-6, IL-10, and IL-21
To determine whether TRAPs impact CD4+ T cell func-
tion, we first isolated TRAPs from the culture superna-
tants of mouse B16F10 melanoma cells [18, 19]. The
TRAPs preparation specifically contained the mature
autophagosome marker LC-3II (Fig. 1a, b) and exhibited
an average size of 436.3 nm, which was distinct from
isolated exosomes that had an average size of 85.6 nm
(Fig. 1c) and expressed the exosome markers CD63 and
TSG101 (Fig. 1d). Treatment of mouse splenic CD4+ T
cells with TRAPs during activation by anti-CD3 and
anti-CD28 resulted in the induction of the transcripts
encoding Il6, Il21, Il10, and Il17, but not Il1b, Il2, Il4,
Il9, Tnf, Ifng, Foxp3 or Tgfb1 (Additional file 2: Figure
S1a). Consistently, the frequency of IL-6+, IL-10+ or IL-
21+ CD4+ T cells and the secretion of IL-6, IL-10 or IL-
21 by CD4+ T cells were increased by TRAPs treatment
(Fig. 1e, f ). TRAPs-induced IL-21+ CD4+ T cells
expressed elevated levels of the follicular helper T cell
(Tfh)-associated molecules CXCR5 and Bcl-6 (Add-
itional file 2: Figure S1b, c). In contrast, TRAPs reduced
the frequency of IFN-γ+ CD4+ T cells (Fig. 1e) and
suppressed IL-12-mediated induction of IFN-γ+ Th1
cells (Additional file 2: Figure S1d). Depletion of TRAPs
from the culture media via ultracentrifugation (Add-
itional file 2: Figure S1e) resulted in a significant reduc-
tion of IL-6, IL-10 and IL-21 production by CD4+ T cells
(Fig. 1g). Intriguingly, we also found that LC3B+ EVs
(TRAPs) purified from B16F10 culture supernatant were
more potent than LC3B− EVs and exosomes in upregu-
lating IL-6 expression, suggesting that LC3B+ EVs
(TRAPs) are the dominant large EVs that instruct CD4+
T cells (Additional file 2: Figure S2a-d). In order to as-
certain the role of TRAPs in inducing IL-6, IL-10 and
IL-21 production by CD4+ T cells in vivo, normal saline
(NS) or TRAPs were administered intravenously (i.v.)
into C57BL/6 mice every other day for 3 times. The fre-
quencies of IL-6+, IL-10+ and IL-21+ CD4+ T cells in the
inguinal lymph node and spleen increased markedly
after TRAPs administration (Fig. 1h). Consistently, in
B16F10 tumor-bearing mice, the frequency of IL-6+, IL-
21+ and IL-10+ CD4+ T cells in the draining lymph node
and spleen were also increased (Fig. 1i). Taken together,
these results show that TRAPs could modulate CD4+ T
cell differentiation by inducing IL-6, IL-10, and IL-21 ex-
pression and suppressing their IFN-γ production.
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TRAPs-induced IL-6, IL-10, and IL-21 production requires
TLR2–MyD88 signaling
We then investigated the mechanism by which TRAPs
induce IL-6, IL-10, and IL-21 in CD4+ T cells. Within
the time frame of the induction of these cytokines,
TRAPs adhered to the surface of CD4+ T cells in a dose-
dependent manner without being internalized (Fig. 2a,
b), suggesting the involvement of surface molecules on
TRAPs that interact with receptors on CD4+ T cells.
TRAPs are enriched with various danger-associated mo-
lecular patterns (DAMPs) capable of stimulating pattern
recognition receptors (PRRs) [17, 18]. CD4+ T cells
expressed appreciable levels of TLR2 and TLR4 (Add-
itional file 2: Figure S3a). We therefore examined
whether TLR2 or TLR4 was involved in sensing TRAPs
by CD4+ T cells. While TRAPs-induced IL-6, IL-10 and
Fig. 1 TRAPs induce IL-6, IL-10, and IL-21 expression by CD4+ T cells. a–d Characterization of TRAPs from B16F10 cells, including Western blot (a,
d), flow cytometric (b), and dynamic light scattering (c) analyses of the expression of the autophagosome-specific marker LC-3II, the percentage,
and the size distribution of the isolated TRAPs. e Flow cytometric determination of the percentage of IL-6-, IL-21-, IL-10-, IL-4-, IL-17-, IFN-γ-, and
Foxp3-expressing CD4+ T cells treated with control media (CM) or 3 μg/ml TRAPs in the presence of anti-CD3 and anti-CD28 for 72 h. f ELISA of
IL-6, IL-10, and IL-21 secretion by CD4+ T cells treated with CM or 1, 3, or 10 μg/ml TRAPs in the presence of anti-CD3 and anti-CD28 for 72 h. g
ELISA of IL-6, IL-10 and IL-21 secretion by CD4+ T cells cultured in B16F10 tumor cell-conditioned culture media, TRAP-depleted tumor cell culture
media or TRAPs purified from the equal cell culture media in the presence of anti-CD3 and anti-CD28 for 72 h. h Flow cytometric and statistical
analyses of the percentage of IL-6+, IL-10+ or IL-21+ CD4+ T cells in the inguinal lymph nodes (iLN) and spleens of C57BL/6 mice (n = 6) 7 days
after i.v. administration of normal saline (NS) or TRAPs (30 μg/mouse) every other day for 3 times. i Flow cytometric and statistical analyses of the
percentage of IL-6+, IL-10+ or IL-21+ CD4+ T cells in the draining lymph nodes (dLN) and spleens of C57BL/6 tumor-bearing (TB) mice (n = 6) 21
days after s.c. inoculation of B16F10 cells, in comparison to the tumor-free (TF) mice. Data (mean ± SEM) represent 3 independent experiments. *,
P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant, by one-way ANOVA with the Tukey-Kramer multiple test, 2-tailed unpaired t-test or Mann-
Whitney U test
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IL-21 secretion by CD4+ T cells was independent of
TLR4, Tlr2−/− and Myd88−/− CD4+ T cells were com-
pletely defective in producing these cytokines in re-
sponse to TRAPs (Fig. 2c). Consistently, TLR2 on the
surface of CD4+ T cells was in direct contact with
TRAPs (Fig. 2d). In agreement with the above finding,
Tlr2−/− mice bearing B16F10 tumors had a significant
reduction of IL-21+ and IL-10+ CD4+ T cells in the
tumor tissue compared to WT tumor-bearing mice (Fig.
2e, f ). Collectively, these results show that TRAPs in-
duce CD4+ T cells to produce IL-6, IL-10, and IL-21 in a
TLR2- and MyD88-dependent manner.
TRAPs-elicited IL-6 production by CD4+ T cells depends
on NF-κB/p38/Akt signaling
We further sought to determine the signals downstream
of TLR2 in the induction of IL-6, IL-10, and IL-21 by
TRAPs. TRAPs treatment of WT CD4+ T cells resulted
in the phosphorylation of NF-κB, Akt, p38 and STAT3,
but not ERK1/2 or JNK1/2 (Fig. 3a), whereas TRAPs
failed to induce NF-κB, Akt, p38 and STAT3 phosphor-
ylation in Tlr2−/− or Myd88−/− CD4+ T cells when com-
pared to CD4+ T cells from WT or Tlr4−/− mice
(Additional file 2: Figure S3b). Pretreatment of CD4+ T
cells with an inhibitor of NF-κB, Akt or p38 attenuated
TRAPs-induced secretion of IL-6, IL-10 and IL-21,
whereas the inhibition of JNK1/2 or ERK1/2 had no ef-
fect (Fig. 3b). Of note, pretreatment of CD4+ T cells with
a STAT3 inhibitor diminished the production of IL-10
and IL-21, but not IL-6, in a dose-dependent manner
(Fig. 3b, c), indicating that NF-κB, Akt, and p38 activa-
tion was needed for TRAPs-induced IL-6, IL-10 and IL-
21 production but STAT3 activation was only required
for IL-10 and IL-21 production.
The induction of IL-10 and IL-21 depends on autocrine IL-
6 signaling
The IL-6–STAT3 pathway plays a crucial role in Th
cell differentiation [22]. Upon IL-6 neutralization with
a blocking antibody, the induction of IL-21 and IL-10
mRNA and proteins by TRAPs was completely abol-
ished, with a concomitant decline of STAT3 phos-
phorylation (Fig. 3d, Additional file 2: Figure S4a).
Consistently, TRAPs failed to induce IL-10 and IL-21
expression or STAT3 phosphorylation in Il6−/− CD4+
T cells (Fig. 3e, Additional file 2: Figure S4b). More-
over, following i.v. administration of TRAPs, the fre-
quencies of IL-10+ and IL-21+ CD4+ T cells in the
Fig. 2 TRAPs induce IL-6/IL-10/IL-21 production of CD4+ T cells via TLR2-MyD88 pathway. a Confocal microscopy analysis of CFSE-labeled TRAPs
(3 μg/ml) and mouse splenic CD4+ T cells (stained with anti-CD4-PE) after 24 h of co-culture. Scale bar: 5 μm. b Flow cytometric determination of
the proportion of CFSE+ CD4+ T cells after incubated with CFSE-labeled TRAPs (0, 1, 3, or 10 μg/ml) in the presence of anti-CD3 and anti-CD28 for
24 h. c ELISA of IL-6, IL-10, and IL-21 secretion by WT, Tlr2−/−, Tlr4−/− or Myd88−/− CD4+ T cells treated with TRAPs (3 μg/ml) or control media (CM)
in the presence of anti-CD3 and anti-CD28 for 72 h. d Purified CD4+ T cells were co-cultured with CFSE-labeled TRAPs (3 μg/ml) for 24 h, and then
stained for TLR2 and analyzed by confocal microscopy. e, f Flow cytometric and statistical analyses of the percentage of IL-10+ CD4+ T cells (e) or
IL-21+ CD4+ T cells (f) in the tumor tissues of WT or Tlr2−/− C57BL/6 mice (n = 6) 21 days after s.c. inoculation of B16F10 cells. Data (mean ± SEM)
represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant, by 2-tailed unpaired t-test or Mann-Whitney U test
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inguinal lymph node and spleen were much lower in
Il6−/− mice than in WT mice (Fig. 3f, g). Collectively,
these results support a TRAPs-initiated regulatory
cascade of CD4+ T cell differentiation involving
TLR2–NF-κB/p38/Akt-dependent induction of auto-
crine IL-6 which then promotes IL-10 and IL-21 ex-
pression via STAT3.
Hsp90α is a TRAPs surface ligand that induces IL-6 in
CD4+ T cells
To identify the molecular components in TRAPs that
are responsible for stimulating CD4+ T cell production
of IL-6, we first subjected TRAPs to proteinase K diges-
tion or sonication. These treatments impaired the ability
of TRAPs to induce IL-6 from CD4+ T cells (Fig. 4a, b),
Fig. 3 TRAPs promote CD4+ T cell expression of IL-6 in an NF-κB/p38/Akt-dependent manner and induce IL-10 and IL-21 via IL-6–STAT3 signaling. a
Western blot analyses of the phosphorylation of JNK, ERK, p38, Akt, IKKα/β, IκBα, p65 and STAT3 in CD4+ T cells treated with TRAPs (3 μg/ml) for the
indicated time. b CD4+ T cells pre-treated with the indicated inhibitors for 1 h and then co-cultured with TRAPs (3 μg/ml) for 72 H. IL-6, IL-10 and IL-21
levels in the supernatants were determined by ELISA. c Western blot analyses of the phosphorylation of STAT3 in CD4+ T cells pre-treated with the
STAT3 inhibitor Stattic at the indicated concentrations (0.5, 1 or 2 μM) for 1 h, and then co-cultured with TRAPs (3 μg/ml) for 2 h. ELISA of IL-10 and IL-
21 secretion by CD4+ T cells treated as above for 72 h. d Western blot analyses of the phosphorylation of STAT3 in CD4+ T cells treated with anti-IL-6
neutralizing antibody (1 μg/ml) and TRAPs (3 μg/ml) for 2 h. ELISA of IL-10 and IL-21 secretion by CD4+ T cells treated as above for 72 h. e Western blot
analyses of the phosphorylation of STAT3 in WT or Il6−/− CD4+ T cells treated with TRAPs (3 μg/ml) for 2 h and ELISA of IL-10 and IL-21 secretion by WT
or Il6−/− CD4+ T cells for 72 h. f, g Flow cytometric and statistical analyses of the percentage of IL-21+ CD4+ T cells (f) or IL-10+ CD4+ T cells (g) in the
iLN and spleens of WT or Il6−/− C57BL/6 mice (n = 6) 7 days after i.v. administration of normal saline (NS) or TRAPs (30 μg/mouse) every other day for 3
times. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant by one-way ANOVA with the
Tukey-Kramer multiple test, 2-tailed unpaired t-test or Mann-Whitney U test
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indicating that proteins on the surface, but not the sol-
uble contents, of TRAPs are largely responsible for IL-6
induction in CD4+ T cells. In addition, TRAPs from the
hepatic carcinoma Hepa1–6, lung cancer LLC or lymph-
oma EL4 cells also potently enhanced IL-6 secretion in
CD4+ T cells (Additional file 2: Figure S5a). Several li-
gands of TLR2, including HMGB1, Hsp60, Hsp70, and
Hsp90α [18, 23], were enriched in and present on the
surface of TRAPs (Fig. 4c, Additional file 2: Figure S5b).
Blocking of Hsp90α, but not HMGB1, Hsp60 or Hsp70,
Fig. 4 Hsp90α on intact TRAPs is essential for IL-6 induction in CD4+ T cells. a, b ELISA of IL-6 secretion by CD4+ T cells treated with TRAPs (3 μg/
ml), proteinase K-digested TRAPs (a) or sonicated TRAPs (b) for 72 h in the presence of anti-CD3/CD28. c Flow cytometric determination of the
Hsp60, Hsp70, Hsp90α, or HMGB1 expression levels on the surface of TRAPs from B16F10 tumor cells. d ELISA of IL-6 secretion by CD4+ T cells
treated with TRAPs (3 μg/ml) or blocking antibody-pretreated TRAPs (anti-HMGB1, anti-Hsp60, anti-Hsp70, anti-Hsp90α antibodies) for 72 h in the
presence of anti-CD3/CD28. e-g CFSE-labeled TRAPs were pretreated with the indicated dose of functional an anti-Hsp90α antibody or an
isotype-matched control antibody overnight at 4 °C and then co-cultured with purified CD4+ T cells in the presence of anti-CD3/CD28. Twenty-
four hour later, the percentage of CFSE+ CD4+ T cells was assessed by flow cytometry (e, f). Seventy-two hour later, IL-6 levels in supernatants
were determined by ELISA (g). h The Hsp90α level in tumor cell lysates, an equal amount of TRAPs, sonicated TRAPs, and proteinase K-pretreated
TRAPs was determined by western blot. Purified CD4+ T cells were co-cultured with the above stimulators for 72 H. IL-6 levels in the supernatants
were determined by ELISA. i ELISA of IL-6 secretion by human CD4+ T cells treated with 3 μg/ml human TRAPs (hTRAPs) from 3 human tumor
cell lines (A375, MDA-MB-231 and HepG2 cells) or 8 tumor patient effusions and ascites, respectively for 72 h in the presence of anti-CD3/CD28. j
ELISA of IL-6 secretion by human CD4+ T cells treated with hTRAPs (3 μg/ml) or anti-Hsp90α-pretreated hTRAPs for 72 h in the presence of anti-
CD3/CD28. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ns, not significant by one-way ANOVA with the
Tukey-Kramer multiple test
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on the surface of TRAPs partially diminished TRAPs-
induced IL-6 secretion by CD4+ T cells, indicating that
other molecules on TRAPs may also play a role (Fig. 4d)
. Accordingly, an anti-Hsp90α antibody dose-dependently
inhibited TRAPs binding to CD4+ T cells (Fig. 4e, f ), re-
duced TRAPs-induced IL-6 secretion (Fig. 4g), and sup-
pressed the activation of NF-κB, Akt and p38
(Additional file 2: Figure S5c). Remarkably, compared to
intact TRAPs, tumor cell lysates containing an equal
amount of total protein but much more Hsp90α, or soni-
cated TRAPs containing an equal amount of Hsp90α, or
proteinase K-treated TRAPs were much less effective in
inducing IL-6 secretion from CD4+ T cells (Fig. 4h). Taken
together, these results show that membrane-bound
Hsp90α on intact TRAPs effectively induces IL-6 expres-
sion from CD4+ T cells.
To further determine whether human TRAPs (hTRAPs)
could induce human CD4+ T cells to produce IL-6, we
collected hTRAPs from the culture media of 3 human
tumor cell lines, A375, MDA-MB-231 and HepG2, and
from the malignant effusions or ascites of 8 cancer pa-
tients (Additional file 1: Table S1). Western blotting ana-
lysis revealed that LC3-II was expressed at high levels in
the collected hTRAPs and Hsp90α was detected in most
of hTRAPs (Additional file 2: Figure S5d). RT-PCR ana-
lysis and ELISA showed that hTRAPs from cancer patients
and tumor cell lines efficiently induced human peripheral
blood CD4+ T cells to express IL6 transcript and secrete
IL-6 (Fig. 4i, Additional file 2: Figure S5e). Similar to
mouse TRAPs, hTRAPs-induced IL-6 transcription and
secretion by human CD4+ T were almost completely abol-
ished by pretreatment of hTRAPs with an anti-hsp90α
blocking antibody (Fig. 4j, Additional file 2: Figure S5f).
Altogether, these results indicate that induction of CD4+
T cells IL-6 expression by HSP90α on the surface of
TRAPs is a common characteristic in humans and mice.
TRAPs-elicited CD4+ T cells (TTRAP) suppress effector T
cells and promote tumorigenesis
To characterize the function of TRAPs-elicited CD4+ T
cells (TTRAP), we activated CD4
+ and CD8+ T cells with
anti-CD3 and anti-CD28 in culture supernatants har-
vested from TTRAP or control CD4
+ T cells. TTRAP su-
pernatants (SN/TTRAP) strongly suppressed the secretion
of IFN-γ by activated CD4+ and CD8+ T cells (Fig. 5a).
Pretreatment of SN/TTRAP with a neutralizing antibody
against IL-6 or IL-10, but not IL-21, abolished its sup-
pressive effect on IFN-γ production by activated CD4+
and CD8+ T cells (Fig. 5b). We then transferred control
CD4+ T cells or TTRAP into C57BL/6 mice that had re-
ceived OVA-specific Vβ5.1+CD8+ OT-I T cells and vacci-
nated with OVA-loaded dendritic cells (DCOVA). DCOVA
vaccination induced the expansion of Vβ5.1+CD8+ OT-I
T cells in the host, which was suppressed by the adoptive
transfer of TTRAP but not control CD4
+ T cells (Fig. 5c).
Moreover, the transfer of TTRAP but not control CD4
+ T
cells led to a decrease of IFN-γ+ CD8+ and CD4+ T cells
induced by DCOVA vaccination (Fig. 5d). Therefore,
TTRAP could suppress T cell IFN-γ response in vivo.
To see whether TTRAP have a tumor-promoting effect
in vivo, we subcutaneously (s.c.) inoculated B16F10
melanoma cells into C57BL/6 mice with or without co-
administration of control CD4+ T cells or TTRAP. Co-
administration of B16F10 cells with TTRAP enhanced
tumor growth as compared to inoculation of B16F10
cells alone or co-administration with control CD4+ T
cells (Fig. 5e). When B16F10 melanoma cells were inoc-
ulated i.v. together with TTRAP, TTRAP promoted tumor
metastasis to the lung (Fig. 5f ). Collectively, these results
show that TTRAP could promote tumor growth and me-
tastasis in vivo.
TTRAP enhance regulatory B cell function via IL-6, IL-10,
and IL-21
To better define the immunosuppressive capacity of
TTRAP, we examined the impact of TTRAP on regulatory
B cell (Breg) differentiation. In accordance with our earl-
ier findings [18], TRAPs induced B cell differentiation
into IL-10-producing Bregs (Fig. 6a). Moreover, co-
culture of B cells and CD4+ T cells in the presence of
TRAPs led to a marked increase in Bregs differentiation
(Fig. 6a). Consistently, SN/TTRAP could directly promote
IL-10+ Bregs differentiation and IL-10 secretion (Add-
itional file 2: Figure S6a, b). Next, adoptive transfer of
TTRAP, but not control CD4
+ T cells, also significantly in-
creased the frequency and number of IL-10+ Bregs in
vivo (Fig. 6b). Therefore, TRAPs can promote IL-10+
Breg differentiation directly by activating on B cells and
indirectly by conditioning CD4+ T cells.
We then investigated the mechanism by which TTRAP
promote IL-10+ Bregs differentiation. In agreement with
the above results, culturing B cells in SN/TTRAP together
with TRAPs resulted in a synergistic increase the fre-
quencies of IL-10+ Bregs and IL-10 secretion as com-
pared to TRAPs or SN/TTRAP alone, whereas the
supernatant of control CD4+ T cells did not have this ef-
fect (Fig. 6c). Neutralizing IL-6, IL-10 or IL-21 partially
abolished the effect of SN/TTRAP in promoting IL-10
production of TRAPs-induced B cells (Fig. 6c). These
data indicate that secreted cytokines, including IL-6, IL-
10, and IL-21, from TTRAP were involved in promoting
Bregs differentiation.
Subsequently, the potential regulatory effect of B cells
pretreated by TRAPs and SN/TTRAP (BTRAP + SN/TTRAP)
on the antitumor effector function of T cells was
assessed. IFN-γ production by activated CD4+ and CD8+
T cells was strongly suppressed when these cells were
cultured in the supernatants from BTRAP + SN/TTRAP (SN/
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BTRAP + SN/TTRAP), and the suppressive activity of the
SN/BTRAP + SN/TTRAP on IFN-γ production by T cell was
largely abolished using an anti-IL-10 neutralizing anti-
body (Fig. 6d). To further investigate the suppressive ef-
fects of BTRAP + SN/TTRAP on effector T cell response in
vivo, C57BL/6 mice, with or without adoptive transfer of
OT-I cells were vaccinated with DCOVA and
subsequently were adoptively transferred with BTRAP +
SN/TTRAP, or BTRAP. DCOVA vaccination induced the ex-
pansion of Vβ5.1+CD8+ OT-I T cells in the recipient
mice. Adoptive transfer of BTRAP inhibited the expansion
of OT-I T cells, and the transfer of BTRAP + SN/TTRAP re-
sulted in a more pronounced and almost complete in-
hibition of the expansion of OT-I T cells (Fig. 6e).
Fig. 5 IL-6/IL-10 from TTRAP is responsible for tumor growth and metastasis. a Flow cytometric and statistical analyses of the percentage of IFN-γ+
CD4+ and CD8+ T cells treated with the supernatants from TTRAP (SN/TTRAP) or control CD4
+ T cells for 3 d in the presence of anti-CD3/CD28. b SN/
TTRAP was pretreated with anti-IL-6, IL-10, IL-21 neutralizing antibodies respectively, and then co-cultured with the purified CD4
+ T cells and CD8+ T cells
in the presence of anti-CD3/CD28 for 3 d. The percentages of IFN-γ+ CD4+ T cells and CD8+ T cells were evaluated by flow cytometry. c C57BL/6 mice
were adoptively transferred i.v. with OT-I spleen cells and then vaccinated s.c. with OVA-loaded DC on day 1, 4 and 7, following injection i.v. with TTRAP
or control CD4+ T cells on day 2, 5 and 8. On the 15th day, the frequencies and the number of Vβ5.1+CD8+ T cells in spleen were analyzed by flow
cytometry. d C57BL/6 mice were vaccinated with OVA-loaded DC and following adoptively transferred with TTRAP or CD4
+ T cells. On the 15th day, the
splenocytes were re-stimulated with OVA-protein for 24 h, and the frequencies of IFN-γ+ T cells were determined by flow cytometry. e B16F10 tumor
cells were mixed with TTRAP or control CD4
+ T cells and injected s.c. into C57BL/6 mice (n = 6 per group). The growth of the tumor was monitored. f
B16F10 tumor cells were intravenously injected into C57BL/6 mice (n = 4 to 6 per group) to establish a lung metastasis model. Subsequently, TTRAP or
control CD4+ T cells were adoptively transferred i.v. 3 times with 1 d of interval. Three weeks later, the tumor nodules in the lungs were examined.
Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant, by 1-way ANOVA with the Tukey-
Kramer multiple test, 2-tailed unpaired t-test or Mann-Whitney U test
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Moreover, adoptive transfer of BTRAP + SN/TTRAP de-
creased the numbers of IFN-γ+ CD8+ and CD4+ T cells
induced by DCOVA vaccination (Fig. 6f ) and promoted
the growth of B16F10 melanoma cells and their metasta-
sis to the lung (Fig. 6g, h). Taken together, these results
suggest that IL-6, IL-10, and IL-21 from TTRAP augment
the differentiation and immunosuppressive function of
TRAPs-induced B cells to facilitate tumor growth and
metastasis.
Inhibition of autophagosomes formation or IL-6 secretion
delay tumor growth
Having shown a critical role of TRAPs in the inhibition
of anti-tumor immunity, we explored whether inhibition
of TRAPs formation by targeting Becn1, a gene essential
for autophagosome formation, could abolish the gener-
ation of tumor-promoting TTRAP (Additional file 2:
Figure S7a, b). Becn1 knock-down in B16F10 cells di-
minished intracellular LC3-II accumulation and mark-
edly reduced TRAPs secretion (Additional file 2: Figure
S7b, c). The culture media collected from Becn1 knock-
down B16F10 cells had reduced ability to induce IL-6,
IL-10, and IL-21 in CD4+ T cells (Fig. 7a). In the mice
bearing knock-down B16F10 tumors, the frequency of
IL-21+ and IL-10+ CD4+ T cells in the tumor draining
lymph node and tumor tissue and the serum IL-6 level
were significantly reduced as compared to those in the
mice bearing control tumors (Fig. 7b–d). Moreover, the
frequency of IL-10+ B cells and IFN-γ+CD4+ T cells in
mice bearing Becn1 knock-down tumors was markedly
decreased and increased, respectively (Fig. 7e, f ). Add-
itionally, Becn1 knock-down B16F10 cells exhibited sig-
nificantly slower growth in vivo (Additional file 2: Figure
S7d). These results indicate that inhibition of tumor
Fig. 6 TTRAP enhance Breg differentiation and function via IL-6, IL-10, and IL-21. a Flow cytometric assessment of IL-10 expression by splenic B
cells after 3 d of co-culture with 3 μg/ml TRAPs or 3 μg/ml TRAPs and an equal number of CD4+ T cells. b TTRAP were adoptively (i.v.) transferred into
C57BL/6 mice (n= 3 per group) every other day for 3 times. The frequency and number of splenic IL-10+ Bregs 7 days after the last transfer of TTRAP was
determined by flow cytometry. c SN/TTRAP was pretreated with an anti-IL-6, −IL-10 or -IL-21 neutralizing antibody and co-cultured with splenic B cells and
TRAPs for 72 h. The numbers of IL-10+ Bregs and IL-10 secretion were determined by flow cytometry and ELISA, respectively. d The supernatants from B
cells stimulated with 3 μg/ml TRAPs and SN/TTRAP (SN/BTRAP + SN/TTRAP) were untreated or pre-treated with an anti-IL-10 neutralizing antibody and then
used to culture anti-CD3/28-activated CD4+ or CD8+ T cells for 3 days. The percentage of IFN-γ+ T cells was determined by flow cytometry. e C57BL/6
mice were i.v. injected with OT-I splenocytes and vaccinated s.c. with DCOVA on day 1, 4 and 7, following adoptive transfer of B cells induced by TRAPs
(BTRAP) or by TRAPs and SN/TTRAP (BTRAP + SN/TTRAP) on day 2, 5 and 8. On day 15, the frequency and the number of Vβ5.1+CD8+ T cells in spleens were
analyzed by flow cytometry. f C57BL/6 mice were vaccinated with DCOVA and transferred with BTRAP or BTRAP + SN/TTRAP. At day 15, the frequencies of
splenic IFN-γ+ CD4+ and CD8+ T cells were determined after ex vivo re-stimulation. g, h B16F10 tumor cells were mixed with BTRAP, BTRAP + SN/CD4+ T, or
BTRAP + SN/TTRAP and injected s.c. into C57BL/6 mice (n= 4 per group). The growth of tumor was monitored (g). B16F10 tumor cells were injected i.v. into
C57BL/6 mice (n= 4 per group) to establish a lung metastasis model. Subsequently, the above-prepared B cells were i.v. transferred every other day for 3
times. Three weeks later, tumor nodules in the lungs were examined (h). Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P<
0.01, ***, P < 0.001; ns, not significant
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Fig. 7 (See legend on next page.)
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autophagosome formation and release could enhance
anti-tumor immunity and inhibit tumor growth in vivo.
Furthermore, the growth of both the negative control
and Becn1 knock-down B16F10 tumors was inhibited in
mice depleted of B cells or CD4+ T cells (Fig. 7g, Add-
itional file 2: Figure S8). Depletion of CD8+ T cells resulted
in accelerated growth of Becn1 knock-down but not nega-
tive control tumors (Fig. 7g, Additional file 2: Figure S8).
Besides, the frequency of IFN-γ-producing CD4+ T cells
and CD8+ T cells in Becn1 knock-down tumor tissue was
markedly increased (Fig. 7h, i). Notably, B-cell or CD4+ T-
cell depletion resulted in a significant increase of the per-
centage of intra-tumoral IFN-γ+ CD4+ or CD8+ T cells
(Fig. 7h, i). The frequency of tumor-infiltrating B cells was
markedly reduced upon CD4+ T cell depletion (Fig. 7j).
These results suggest that the effector function of CD8+ T
cells in the tumors was dampened by CD4+ T cells or B
cells. In conclusion, TRAPs-educated CD4+ T cells play an
important role in promoting tumor growth by inhibiting
effector T cell function.
To determine the role of CD4+ T cell-derived IL-6 in
the differentiation of IL-10- and IL-21-producing CD4+
T cells and IL-10-producing Bregs in vivo, WT or Il6−/−
mice were s.c. inoculated with B16F10 cells. Consistent
with previous results, the frequencies of IL-10+ and IL-
21+ CD4+ T cells (Fig. 7k, l) and IL-10+ B cells (Fig. 7m)
in tumor-draining lymph nodes and tumor tissues from
Il6−/− tumor-bearing mice were significantly decreased.
Accordingly, B16F10 tumors grew more slowly in Il6−/−
mice than in WT mice (Fig. 7n). We then inoculated
mice with B16F10 cells together with either WT TTRAP
or Il6−/− TTRAP. Mice co-inoculated with B16F10 cells
and WT TTRAP showed accelerated growth and lung
metastasis as compared to those inoculated with B16F10
cells alone (Fig. 7o-q). In contrast, co-inoculation of
B16F10 cells with Il6−/− TTRAP resulted in no
enhancement of tumor growth and lung metastasis, and
the mice even exhibited slightly, albeit not statistically
significant, retarded tumor growth (Fig. 7o-q). These re-
sults corroborate the conclusion that TTRAP rely on IL-6
to dampen T cell-mediated antitumor immunity and fos-
ter tumor progression, and suggest that targeting TRAPs
or IL-6 may be an effective therapeutic strategy for im-
proving cancer immunotherapy.
Discussion
In addition to soluble factors, tumor cell-derived extra-
cellular vesicles are being recognized as critical modula-
tors of host anti-tumor immunity during tumor
progression [7, 8, 18, 19, 24]. Among them are autopha-
gosomes generated by secretory autophagy. In contrast
to canonical autophagy that functions in a primarily de-
gradative capacity to sustain cellular metabolism and
homeostasis and is often induced conditions of cellular
stress, such as nutrient starvation, organelle damage,
and pathogen infection, secretory autophagy is a non-
degradative mechanism for cellular trafficking and un-
conventional protein secretion [10, 11, 13, 14, 25].
Secretory autophagosomes fail to fuse with lysosomes,
but are released into the extracellular environment
through fusing with the plasma membrane or other
pathways [15, 26]. Abundant autophagosomes have been
detected in gastrointestinal tumors and invasive melano-
mas and have been associated with tumor cell prolifera-
tion, metastasis, and poor prognosis [27, 28]. Our
previous studies showed that extracellular autophago-
somes harvested from the supernatant of tumor cells or
malignant effusions and ascites of cancer patients, which
we have termed as TRAPs, could promote the gener-
ation of IL-10+ Bregs, reactive oxygen species (ROS)-
producing neutrophils, and PD-L1hi macrophages exert-
ing immunoinhibitory activities [18–20].
(See figure on previous page.)
Fig. 7 Knockdown of Beclin1 or knockout of IL-6 inhibits tumor growth and alters CD4+T and B cells polarization. a ELISA of IL-6, IL-10, and IL-21
secretion by CD4+ T cells treated with CM, or media from negative control (NC) or Becn1-knockdown (KD) B16F10 cells in the presence of anti-
CD3/CD28 for 72 h. b-f Control (NC) or Becn1-KD B16F10 cells were inoculated s.c. into C57BL/6 mice (n = 6 per group). Twenty-one days later,
serum IL-6 level was measured by ELISA (b). The frequency of IL-10+ CD4+ T cells (c), IL-21+ CD4+ T cells (d), IFN-γ+ CD4+ T cells (e),
and IL-10+ B cells (f) in tumor-draining lymph nodes (dLN) or tumor tissues (Tumor) were analyzed by flow cytometry. g-j The tumor-
bearing mice (n = 5 per group) were depleted of either CD4+ or CD8+ T cells or CD20+ B cells by intravenous administration of
250 μg/mouse of anti-mouse CD4 or anti-mouse CD8 antibodies twice weekly throughout the course of tumor growth, or 250 μg of
anti-mouse CD20 antibodies, respectively. Control mice were treated with isotype-matched control antibodies. g Tumor growth was
monitored by calipers. h, i The frequency of CD4+ IFN-γ+ and CD8+ IFN-γ+ T cells in tumor infiltrating lymphocytes were determined
by intracellular staining. j The frequency of B cells in tumor infiltrating lymphocytes were determined by flow cytometry. k-n WT or
Il6−/− C57BL/6 mice were inoculated s.c. with B16F10 cells. On day 21, the frequencies of IL-10+ CD4+ T cells (k), IL-21+ CD4+ T cells (l),
and IL-10+ B cells (m) in dLN and tumor tissues were evaluated by flow cytometry. n Tumor size was measured by caliper. o, p B16F10 tumor cells
were mixed with WT TTRAP or Il6
−/− TTRAP and injected s.c. into C57BL/6 mice (n = 6 per group). The growth of the tumor was monitored. o, q B16F10
tumor cells were i.v. injected into C57BL/6 mice (n = 6 per group). Subsequently, WT TTRAP or Il6
−/− TTRAP were transferred i.v. every
other day for 3 times. Three weeks later, tumor nodules in the lungs were examined. r A proposed model for the mechanisms and
immunosuppressive functions of TRAPs-induced CD4+ T cells. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **,
P < 0.01; ***, P < 0.001; ns, not significant, by 1-way ANOVA with the Tukey-Kramer multiple test, 2-tailed unpaired t-test or Mann-
Whitney U test
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CD4+ T cells that infiltrate advanced solid tumors con-
sist of different effector cells, such as Th1, Th2, Th17, Tfh
or regulatory T cells (Tregs), with distinct impact on anti-
tumor immunity, immune escape, angiogenesis and me-
tastasis [2, 4, 29], but the influence of the tumors on CD4+
effector T cell differentiation remains incompletely under-
stood. Here, we have revealed a TRAPs-mediated regula-
tory mechanism of CD4+ T cells differentiation whereby
HSP90α on the surface of TRAPs educate CD4+ T cells via
a TLR2–autocrine IL-6 cascade to express IL-10 and IL-21
and engender immune suppression to promote tumor
growth and metastasis (Fig. 7r). Our findings have re-
vealed TRAPs as one of the tumor-derived extracellular
vesicles that could inhibit anti-tumor immune response by
enhancing the generation of immunosuppressive cells.
TLRs play crucial roles in the innate host defense as
well as the control of adaptive immunity [30, 31]. Our
findings indicated TLR2 as a key receptor for TRAPs-
mediated IL-6 expression by CD4+ T cells. Exogenous
pathogen-associated molecular patterns (PAMPs) and
endogenous DAMPs can be recognized by TLRs to trig-
ger the production of various inflammatory mediators
[30]. The current findings showed that TRAPs-mediated
regulation of CD4+ T cell differentiation involved
membrane-associated Hsp90α. Evidences suggested that
extracellular Hsp90α could be released to the extracellu-
lar space via unconventional secretion, such as exosomes
and necrosis [32]. We observed Hsp90α on the surface
of TRAPs, indicating that secretory autophagosomes
may also be involved in the release of Hsp90α. More-
over, extracellular Hsp90α was reported to function as a
DAMP and provoke biological effects through cell sur-
face receptors, including TLRs and CD91 [23, 33]. Early
work showed that heat shock proteins gp96, Hsp90,
Hsp70, and calreticulin could function as potential adju-
vants to stimulate DC antigen cross-presentation and
maturation through the CD91 receptor [33], but Hsp90α
was more recently found to also stimulate tumor prolif-
eration and metastasis through binding to cancer cell
surface CD91 and be positively correlated with tumor
malignancy in cancer patients [34–36]. The present
study uncovers a new role of Hsp90α on the surface of
TRAPs as a cancer-associated pathological factor that in-
terferes with host anti-tumor immunity.
Chronic inflammation and increased levels of inflam-
matory mediators at the tumor site can reroute the im-
munomodulatory response towards a cancer-promoting
direction [4, 37, 38]. IL-6 has a profound effect on CD4+
T cells survival and proliferation [39]. Otherwise, studies
also showed that IL-6 has inhibitory effects via the in-
duction of IL-10-producing T and B cells [40, 41]. More-
over, IL-6 also dampens Th1 differentiation and inhibits
CD8+ T cell activation and cytokine production [42, 43].
Consistent with the above results, we provided evidences
that TRAPs stimulated IL-10 and IL-21 production in
CD4+ T cells via an autocrine IL-6 loop. Moreover, IL-6
from TTRAP remarkably suppressed T cell anti-tumor ef-
fector function. IL-21 has been identified to be derived
mainly from Tfh cells, which was thought to regulate the
proliferation, class switching, and plasmacytoid differen-
tiation of B cells and promote the generation and prolif-
eration of human antigen-specific cytotoxic T-cell
responses [4, 44, 45]. Mounting evidences have shown
that IL-21 also has anti-inflammatory activities by inhi-
biting DC maturation and stimulating IL-10 production
in T and B cells [46–48]. Nonetheless, the role of CD4+
T cells in Bregs differentiation in the tumor microenvir-
onment has not been addressed. In our investigation, the
IL-21+ TTRAP displayed Tfh-associated molecules
CXCR5 and Bcl-6. Interestingly, IL-6, IL-10, and IL-21
secretion by TTRAP synergistically enhanced TRAPs-
elicited Breg differentiation and immunosuppressive
function. These findings together imply that TTRAP-de-
rived IL-21 is a pleiotropic effector that can either facili-
tate or thwart tumor growth depending on the cytokine
milieu in the tumor microenvironment, warranting care-
ful consideration of the selective targeting of IL-6 or IL-
21 for the treatment of cancer in the future.
Many recent studies have suggested that inhibiting
tumor autophagy may have anti-tumor effects by modu-
lating the tumor microenvironment [49–51]. Consistent
with this notion, we found that inhibiting autophagy by
targeting the key autophagy gene Becn1, which led to a
substantial decrease in extracellular TRAPs, could in-
hibit tumor growth in mice. Of note, inhibiting autoph-
agy resulted in a significant decrease in the frequency of
IL-10+ B cells, IL-21+ and IL-10+CD4+ T cells, as well as
a significant increase in IFN-γ+CD4+ T cells, in the
tumor-draining lymph nodes and tumor tissue. Thus,
intervening tumor release of TRAPs could be an effect-
ive strategy for cancer therapy.
Conclusions
In this study, we have revealed that TRAPs can educate
CD4+ T cells to promote tumor growth and metastasis
through an HSP90α–TLR2–IL-6–IL-10/IL-21 axis and
the induction of IL-10+ Bregs. Our study reveals a novel
cellular and molecular mechanism of how tumor-derived
extracellular vesicles regulate CD4+ effector T cell func-
tion and highlights TRAPs and their membrane-bound
DAMPs as important therapeutic targets to reverse the
immunosuppressive tumor microenvironment.
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